We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Characterization of Brain Metastases

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00184275
First Posted: September 16, 2005
Last Update Posted: March 7, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
The Royal Norwegian Ministry of Health
Information provided by (Responsible Party):
Norwegian University of Science and Technology
  Purpose
The purpose is to characterize tumour biological markers in brain metastases tissue from patients with different primary tumour by using ex vivo techniques as high-resolution magic angle spinning MR spectroscopy and micro array.

Condition
Neoplasm Metastasis Lung Neoplasms Breast Neoplasms Melanoma

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Brain Metastases Tissue Characterized by High-resolution Magic Angle Spinning MR and Micro Array

Resource links provided by NLM:


Further study details as provided by Norwegian University of Science and Technology:

Biospecimen Retention:   Samples With DNA
frozen tumor tissue samples

Enrollment: 26
Study Start Date: May 2005
Study Completion Date: December 2010
Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients with brain metastases
Criteria

Inclusion Criteria:

  • Clinical diagnosis of brain metastases

Exclusion Criteria:

  • children
  • pregnancy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00184275


Locations
Norway
Norwegian University of Science and Technology, Faculty of Medicine
Trondheim, Norway, N-7489
Sponsors and Collaborators
Norwegian University of Science and Technology
The Royal Norwegian Ministry of Health
Investigators
Study Director: Steinar Lundgren, MD PhD Cancer Clinic, St.Olavs Hospital Trondheim University Hospital
Study Chair: Ingrid S Gribbestad, PhD Norwegian University of Science and Technology, Faculty of Medicine
  More Information

Publications:
Responsible Party: Norwegian University of Science and Technology
ClinicalTrials.gov Identifier: NCT00184275     History of Changes
Other Study ID Numbers: 12621
First Submitted: September 13, 2005
First Posted: September 16, 2005
Last Update Posted: March 7, 2014
Last Verified: March 2014

Keywords provided by Norwegian University of Science and Technology:
Brain metastasis
HR MAS spectroscopy
Tissue micro array
DNA micro array

Additional relevant MeSH terms:
Neoplasms
Neoplasm Metastasis
Neoplasms, Second Primary
Breast Neoplasms
Lung Neoplasms
Neoplastic Processes
Pathologic Processes
Neoplasms by Site
Breast Diseases
Skin Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases